Speciality Medicines
Close ·
Key Fundamentals
SMEPrice-based figures at the close · TTM
- ROCE
- 25.30%
- Debt to Equity
- 0.10
- EPS (TTM)
- —
- Book Value
- ₹81.03
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 1.67
- ROE
- 25.60%
- Dividend Yield
- 0.00%
- EBITDA
- ₹14.50 Cr
- 52W High
- ₹381.20
- 52W Low
- ₹121.10
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 10 | 6 | 3 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bearish | 8 | 2 | 0 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 36.40
- Neutral
- MACD (12,26,9)
- −6.55
- Bearish
- SMA (50)
- 154.81
- Bearish
- SMA (200)
- —
- Neutral
As of
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 3Y | +48.29% |
|---|---|
| 1Y | +29.31% |
Net profit
| 3Y | +86.63% |
|---|---|
| 1Y | +44.44% |
Operating cash flow
| 3Y | Outflow narrowed by ₹3 Cr |
|---|---|
| 1Y | Outflow narrowed by ₹5 Cr |
Operating margin· change in pp
| 3Y | +1.28 pp |
|---|---|
| 1Y | +3.15 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2022 | ₹40.00 Cr |
|---|---|
| Mar 2023 | ₹23.00 Cr |
| Mar 2024 | ₹28.00 Cr |
| Mar 2025 | ₹58.00 Cr |
| Mar 2026 | ₹75.00 Cr |
Net profit by year
| Mar 2022 | ₹1.00 Cr |
|---|---|
| Mar 2023 | ₹2.00 Cr |
| Mar 2024 | ₹3.00 Cr |
| Mar 2025 | ₹9.00 Cr |
| Mar 2026 | ₹13.00 Cr |
Quarterly Results
₹ Cr| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 31 | 45 |
| Expenses | 26 | 36 |
| Operating Profit | 4 | 8 |
| OPM % | 14% | 19% |
| Other Income | 0 | 1 |
| Interest | 0 | 1 |
| Depreciation | 0 | 0 |
| PBT | 4 | 8 |
| Tax % | 36% | −1% |
| Net Profit | 3 | 8 |
| EPS (₹) | 4.16 | 9.31 |
Profit & Loss
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 40 | 23 | 28 | 58 | 75 |
| Expenses | 38 | 20 | 22 | 49 | 62 |
| Operating Profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6% | 15% | 19% | 16% | 18% |
| Other Income | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| PBT | 2 | 3 | 5 | 9 | 13 |
| Tax % | 31% | 43% | 36% | 1% | 0% |
| Net Profit | 1 | 2 | 3 | 9 | 13 |
| EPS (₹) | 70.48 | 4.42 | 5.73 | 13.38 | 14.83 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 0.21 | 4 | 5 | 6 | 9 |
| Reserves | 2 | 2 | 10 | 24 | 62 |
| Borrowings | 1 | 4 | 3 | 5 | 7 |
| Other Liabilities | 3 | 4 | 5 | 5 | 17 |
| Total Liabilities | 6 | 13 | 23 | 40 | 95 |
| Fixed Assets | 2 | 2 | 1 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 11 | 21 | 38 | 93 |
| Total Assets | 6 | 13 | 23 | 40 | 95 |
Cash Flow
₹ Cr| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 1 | −4 | −5 | −6 | −1 |
| Investing | −2 | 0 | 0 | −2 | −3 |
| Financing | 2 | 4 | 5 | 8 | 28 |
| Net Cash Flow | 0 | 0 | 0 | 1 | 24 |
| Free Cash Flow | −1 | −4 | −5 | −6 | −1 |
| CFO/OP | 36 | −101 | −66 | −63 | −9 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 23 | 87 | 142 | 60 | 128 |
| Inventory Days | 5 | 103 | 161 | 150 | 191 |
| Days Payable | 12 | 40 | 48 | 8 | 80 |
| Cash Conversion Cycle | 16 | 149 | 255 | 202 | 239 |
| Working Capital Days | −3 | 76 | 185 | 180 | 221 |
| ROCE % | — | 52% | 38% | 34% | 25% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Speciality Medicines insights
48 extracted metrics across FY22–FY26.
Documents
- General announcements 15 Oct 2026
Frequently Asked Questions about Speciality Medicines
Where is Speciality Medicines (SPML) listed?
What is the 52-week high and low of Speciality Medicines?
What is the Return on Equity (ROE) of Speciality Medicines?
Company Information
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544738.md for Speciality Medicines: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.